8-K: SRAX Inc. Amends Preferred Stock Terms, Removes Shareholder Approval Requirement

SRAX Inc. has amended the terms of its Series B Preferred Stock, removing the need for shareholder approval for certain issuances and expanding trading market options.

Summary

• SRAX Inc. filed an amendment to its Series B Preferred Stock Certificate of Designation on March 27, 2024.
• The amendment removes the requirement for shareholder approval for issuing shares to the holder, as previously mandated by NASDAQ rules.
• The amendment also adds OTCQB, OTCQX, and OTC Pink as acceptable trading markets for the stock.
• Section 6(d) of the original certificate, which required shareholder approval for share issuance to the holder, has been removed.
• Section 7(C) has been added, relating to subsequent equity sales.
• The company is authorized to issue 50,000,000 shares of preferred stock, with 118,651 designated as Series B Convertible Preferred Stock.
• The stated value of each share of Series B Preferred Stock is $48.00, and the conversion price is $1.00, subject to adjustments.
• Holders of the preferred stock can convert their shares into common stock at any time.
• The number of shares of common stock received upon conversion is determined by dividing the stated value of the preferred stock by the conversion price.
• The company is required to reserve enough common stock for the conversion of all outstanding preferred shares.

Sentiment

Score: 6

Explanation: The document reflects a neutral corporate action, with both positive and potentially negative implications. The removal of shareholder approval could be seen as a negative, while the addition of OTC markets could be a positive. The overall sentiment is therefore neutral.

Positives

• The removal of the shareholder approval requirement simplifies the process for issuing shares to the preferred stock holder.
• The addition of OTCQB, OTCQX, and OTC Pink as trading markets provides more flexibility and potential liquidity for the stock.
• The conversion feature allows preferred stock holders to convert to common stock at a fixed price of $1.00, subject to adjustments.

Negatives

• The amendment removes a layer of shareholder oversight regarding the issuance of shares to the preferred stock holder.
• The document does not provide any information on the reason for the change.

Risks

• The removal of shareholder approval could potentially dilute existing shareholders if a large number of shares are issued to the preferred stock holder.
• The document does not provide any information on the reason for the change, which could be a concern for investors.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Management Comments

• Christopher Miglino, Chief Executive Officer of SRAX, Inc., certified the amendment to the Certificate of Designation.

Industry Context

The amendment of preferred stock terms is a common corporate action, often used to adjust financing terms or facilitate capital raising. The addition of OTC markets suggests a potential shift in the company's trading strategy or a need to access a broader range of investors.

Comparison to Industry Standards

• The removal of shareholder approval for certain issuances is not uncommon in preferred stock agreements, but it is often a point of negotiation between the company and investors.
• The inclusion of OTC markets is a common practice for companies that may not meet the listing requirements of major exchanges or are seeking to broaden their investor base.
• The conversion price of $1.00 is a common structure for preferred stock, but the specific terms and adjustments are unique to each agreement.

Corporate Governance

Stakeholder Impact

• Shareholders may be impacted by the removal of shareholder approval for certain issuances, potentially leading to dilution.
• Preferred stock holders may benefit from the removal of shareholder approval and the addition of OTC trading markets.
• The company may benefit from increased flexibility in issuing shares and accessing a broader range of investors.

Next Steps

• The company will likely proceed with the amended terms of the Series B Preferred Stock.
• The company may begin trading on the newly added OTC markets.

Key Dates

Keywords

Preferred Stock, Series B, Shareholder Approval, Conversion, OTCQB, OTCQX, OTC Pink, SRAX Inc., Amendment, Trading Market